Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, AstraZeneca Pharma India's average EPS without NRIGrowth Rate was -18.30% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 14.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 22.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 35.50% per year.
During the past 13 years, AstraZeneca Pharma India's highest 3-Year average EPS without NRI Growth Rate was 118.60% per year. The lowest was -35.80% per year. And the median was 18.80% per year.
AstraZeneca Pharma India (NSE:ASTRAZEN) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
AstraZeneca Pharma India Earnings per Share (Diluted) Related Terms
AstraZeneca Pharma India Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for AstraZeneca Pharma India's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India Earnings per Share (Diluted) Chart
NSE:ASTRAZEN vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's PE Ratio distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's PE Ratio falls into.
AstraZeneca Pharma India Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
AstraZeneca Pharma India's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹67.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of ₹67.85 mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Earnings per Share (Diluted) of ₹67.85 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on AstraZeneca Pharma India and its competitors. According to the industry distribution chart, AstraZeneca Pharma India ranks #320 out of 787 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is AstraZeneca Pharma India's Earnings per Share (Diluted) too high?
AstraZeneca Pharma India's current Earnings per Share (Diluted) is ₹67.85. Based on the distribution chart, AstraZeneca Pharma India ranks #320 out of 787 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #320 out of 787 companies for Earnings per Share (Diluted). This puts AstraZeneca Pharma India in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Earnings per Share (Diluted) is ₹67.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,360.10, compared to a current price of ₹7,792.50 — trading 31.4% below its estimated fair value. The current Earnings per Share (Diluted) is ₹67.85. AstraZeneca Pharma India's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Earnings per Share (Diluted) is ₹67.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹7,792.50 is trading 31.4% below its estimated GF Value™ of ₹11,360.10.
GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.
Key valuation signals for NSE:ASTRAZEN:
Earnings per Share (Diluted): ₹67.85
GF Value™: ₹11,360.10 vs. price of ₹7,792.50 (31.4% below fair value)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
90GF Score
Get the complete analysis for NSE:ASTRAZEN
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
